Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group / C. Birbara, J. Breiter, C. Perdomo, W. Hahne // Eur. J. Gastroenterol. Hepatol. — 2000. — Vol. 12. — P. 889-97.
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease / P. Bytzer, A. Blum, D. De Herdt [et al.] // Aliment. Pharmacol. Ther. — 2004. — Vol. 20. — P. 181-8.
Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment / P. Bytzer, A. Morocutti, P. Kennerly [et al.] // Scand. J. Gastroenterol. — 2006. — Vol. 41. — P. 1132-40.
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States / A. Caos, J. Breiter, C. Perdomo, J. Barth // Aliment. Pharmacol. Ther. — 2005. — Vol. 22. — P. 193-202.
Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care — prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg / A. Eggleston, P.H. Katelaris, S. Nandurkar [et al.] // Aliment. Pharmacol. Ther. — 2009 — Vol. 29. — P. 967-78.
Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease — a double-blind, placebo-controlled, randomized study / R. Fass, B. Delemos, L. Nazareno [et al.] // Aliment. Pharmacol. Ther. — 2010. — P. 865-888.
Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia / K.M. Fock, E.K. Teo, T.L. Ang [et al.] // World J. Gastroenterol. — 2005. — Vol. 11. — P. 3091-8.
Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole / Y. Fujiwara, Y. Kohata, M. Kaji [et al.] // Digestion. — 2010. — Vol. 81. — P. 135-41.
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease / G. Holtmann, P. Bytzer, M. Metz [et al.] // Aliment. Pharmacol. Ther. — 2002. — Vol. 15. — P. 479-85.
Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors — focus on rabeprazole / J. Horn // Aliment. Pharmacol. Ther. — 2004. — Vol. 20 (Suppl. 6.). — P. 11-19.
Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease / P.J. Kahrilas, P. Miner, J. Johanson [et al.] // Dig. Dis. Sci. — 2005. — Vol. 50. — P. 2009-18.
The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease / X.H. Liu, M.Y. Ke, Z.Q. Song [et al.] // Zhonghua Nei Ke Za Zhi. — 2005. — Vol. 44. — P. 818-21.
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study / Miner P. Jr, Katz P.O., Chen Y., Sostek M. // Am. J. Gastroenterol. — 2003. — Vol. 98. — P. 2616-20.
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial / Miner P. Jr, Orr W., Filippone J. [et al.] // Am. J. Gastroenterol. — 2002. — Vol. 97. — P. 1332-9.
Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-hour intragastric acidity and oesophageal acid exposure: a randomised, study in gastroesophageal reflux disease (GERD) patients with a history of nocturnal heartburn / P. Miner, B. Delemos, J. Xiang [et al.] // Aliment. Pharmacol. Ther. — 2010. —
Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg / D.G. Morgan, M.F. O’Mahony, W.F. O’Mahony [et al.] // Can. J. Gastroenterol. — 2007. — Vol. 21. — P. 820-6.
Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors / S.V. Morozov, O.M. Tsodikova, V.A. Isakov [et al.] // Eksp. Kl. Gastroenterol. — 2003. — 6. — 58-63
Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole / Y. Muro, K. Sugiura, Y. Nitta [et al.] // Clin. Exp. Rheumatol. — 2009. — Vol. 27. — P. 15-21.
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole / F. Pace, V. Annese, A. Prada [et al.] // Dig. Liver Dis. — 2005. — Vol. 37. — P. 741-50.
A review of rabeprazole in the treatment of acid-related diseases / F. Pace, S. Pallotta, S. Casalini, G.B. Porro // Ther. Clin. Risk Manag. — 2007. — Vol. 3. — P. 363-79.
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis / M. Robinson, S. Fitzgerald, R. Hegedus [et al.] // Aliment. Pharmacol. Ther. — 2002. — Vol. 16. — P. 445-54.
Röhss K. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms / K. Röhss, T. Lind, C. Wilder-Smith // Eur. J. Clin. Pharmacol. — 2004. — Vol. 60. — P. 531-9.
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years / B. Thjodleifsson, G. Rindi, R. Fiocca [et al.] // Aliment. Pharmacol. Ther. — 2003. — Vol. 17. — P. 343-51.
Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn / S. Warrington, K. Baisley, D. Lee [et al.] // Aliment. Pharmacol. Ther. — 2007. — Vol. 25. — P. 511-7.
Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? / N.J. Wit, W.A. Boer, H. Geldof [et al.] // Aliment. Pharmacol. Ther. — 2004. — Vol. 20. — P. 451-8.
Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment / X.L. Yang, X.H. Liu, M.Y. Ke [et al.] // Zhonghua Yi Xue Za Zhi. — 2009 — Vol. 89. — P. 2404-7.